Cogent Biosciences, Inc.

Contributing Author

Recent Articles by Cogent Biosciences, Inc.

Oct-24	Cogent Biosciences Announces KRAS Poster Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics COGT GlobeNewswire
Oct-20	Cogent Biosciences Announces FDA Breakthrough Therapy Designation for Bezuclastinib COGT GlobeNewswire
Sep-29	Cogent Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) COGT GlobeNewswire
Aug-26	Cogent Biosciences Announces Participation in the Citi Biopharma Conference COGT GlobeNewswire
Aug-05	Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2025 Financial Results COGT GlobeNewswire
Jul-10	Cogent Biosciences Announces Closing of Upsized Public Offering of Shares of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares COGT GlobeNewswire
Jul-08	Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock COGT GlobeNewswire
Jul-08	Cogent Biosciences Announces Proposed $150 Million Public Offering of Common Stock COGT GlobeNewswire
Jul-07	Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Advanced Systemic Mastocytosis COGT GlobeNewswire
Jun-11	Cogent Biosciences Secures up to $400 Million in Non-Dilutive Financing COGT GlobeNewswire
May-29	Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference COGT GlobeNewswire
May-06	Cogent Biosciences Reports First Quarter 2025 Financial Results COGT GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.